Upadacitinib effectively treated a patient with multiple inflammatory conditions.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
September 2023 in “Journal of the American Academy of Dermatology” 5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
9 citations
,
November 2023 in “Supportive Care in Cancer” April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
June 2013 in “Annals of the rheumatic diseases” Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
January 2024 in “Faculty of 1000 Research Ltd” Tazarotene gel may be more effective for acne than adapalene gel.
18 citations
,
December 2017 in “Medicine” Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.
May 2026 in “Journal of Clinical Oncology” Later line chemotherapy causes severe side effects, impacting quality of life, but patients continue treatment to extend life and stay connected with loved ones.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
3 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
3 citations
,
February 2023 in “Journal of drug delivery science and technology” The new drug carriers show promise for better targeting and treating ovarian cancer.
23 citations
,
December 2004 in “Seminars in oncology” Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
278 citations
,
May 2013 in “Ca” Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
More research is needed to understand chemotherapy-induced hair loss and its phases.
21 citations
,
May 1989 in “Advanced Drug Delivery Reviews” Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.
17 citations
,
January 2019 in “Journal of cancer” The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.
August 2016 in “Journal of Investigative Dermatology” 45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.
50 citations
,
December 2017 in “Nanoscale” Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.